![Farmak Tafamidis Meglumine](https://www.pharmacompass.com/image/flap/farmak-tafamidis-meglumine-header-desktopgif-42043.gif)
![Farmak Tafamidis Meglumine](https://www.pharmacompass.com/image/flap/farmak-tafamidis-meglumine-header-mobilegif-3470.gif)
1. Fx 1006a
2. Fx-1006a
3. Fx1006a
4. Tafamidis
5. Vyndamax
6. Vyndaqel
1. Vyndaqel
2. 951395-08-7
3. Fx-1006a
4. Fx1006a
5. Fx 1006a
6. Zu7cf08a1a
7. Chebi:79345
8. 951395-08-7 (meglumine)
9. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate
10. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid
11. Unii-zu7cf08a1a
12. Tafamidis Meglumine [usan]
13. Tafamidis Meglumine [usan:inn]
14. Vyndaqel (tn)
15. Chembl2105675
16. Schembl14783506
17. Tafamidis Meglumine [mi]
18. Tafamidis Meglumine (jan/usan)
19. Dtxsid50915094
20. Tafamidis Meglumine [jan]
21. Ex-a3550
22. Hy-14852a
23. Mfcd28502032
24. Tafamidis Meglumine [who-dd]
25. Akos037649321
26. At18247
27. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
28. Tafamidis Meglumine [orange Book]
29. Bs-18043
30. Cs-0045567
31. Pf-06291826
32. D09674
33. Q27148396
34. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate
35. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)
36. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)hexitol (1/1)
37. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
38. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
39. D-gluco-2,3,4,5,6-pentahydroxy-n-methylhexan-1-aminium 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate
Molecular Weight | 503.3 g/mol |
---|---|
Molecular Formula | C21H24Cl2N2O8 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 8 |
Exact Mass | 502.0909711 g/mol |
Monoisotopic Mass | 502.0909711 g/mol |
Topological Polar Surface Area | 177 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 506 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Investigated for use/treatment in amyloidosis.
Neuropathic heredofamilial amyloidosis
Fx-1006A is a first-in-class, disease-modifying compound that is designed to inhibit the formation of amyloid deposits by preventing the misfolding and deposition of the transthyretin protein (TTR), which is associated with amyloidosis.